CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Top Cited Papers
- 1 April 2023
- journal article
- review article
- Published by American Physiological Society in Physiological Reviews
- Vol. 103 (2) , 1565-1644
Abstract
Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse physiological functions. Its two isoforms (α and β) are widely expressed throughout the body in sensory neurons as well as in other cell types, such as motor neurons and neuroendocrine cells. CGRP acts via at least two G protein-coupled receptors that form unusual complexes with receptor activity-modifying proteins. These are the CGRP receptor and the AMY1receptor; in rodents, additional receptors come into play. Although CGRP is known to produce many effects, the precise molecular identity of the receptor(s) that mediates CGRP effects is seldom clear. Despite the many enigmas still in CGRP biology, therapeutics that target the CGRP axis to treat or prevent migraine are a bench-to-bedside success story. This review provides a contextual background on the regulation and sites of CGRP expression and CGRP receptor pharmacology. The physiological actions of CGRP in the nervous system are discussed, along with updates on CGRP actions in the cardiovascular, pulmonary, gastrointestinal, immune, hematopoietic, and reproductive systems and metabolic effects of CGRP in muscle and adipose tissues. We cover how CGRP in these systems is associated with disease states, most notably migraine. In this context, we discuss how CGRP actions in both the peripheral and central nervous systems provide a basis for therapeutic targeting of CGRP in migraine. Finally, we highlight potentially fertile ground for the development of additional therapeutics and combinatorial strategies that could be designed to modulate CGRP signaling for migraine and other diseases.Keywords
Funding Information
- HHS | NIH | National Institute of Neurological Disorders and Stroke (RF1NS113839)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (R01NS075599)
- Veterans Administration Medical Center, Yale School of Medicine (1I01 RX003523-01)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (NS113839)
This publication has 823 references indexed in Scilit:
- Brain-derived neurotrophic factor in primary headachesThe Journal of Headache and Pain, 2012
- Activation of central trigeminovascular neurons by cortical spreading depressionAnnals of Neurology, 2010
- Verisimilitude (or “truthlikeness”) as an alternative to pro and cons: migraine and cluster headache mechanismsThe Journal of Headache and Pain, 2010
- Thalamic sensitization transforms localized pain into widespread allodyniaAnnals of Neurology, 2010
- Calcitonin gene-related peptide differentially regulates gene and protein expression in trigeminal glia cells: Findings from array analysisNeuroscience Letters, 2010
- Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74Biochemical and Biophysical Research Communications, 2010
- Genetic Enhancement of Calcitonin Gene-Related Peptide-Induced Central Sensitization to Mechanical Stimuli in MiceThe Journal of Pain, 2009
- Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A reviewThe Journal of Headache and Pain, 2009
- Sensory innervation of the calvarial bones of the mouseJournal of Comparative Neurology, 2009
- Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal periodThe Journal of Headache and Pain, 2009